Cancer
BRAF and MEK inhibitors
Targeted drugs for tumours with a BRAF V600 mutation, about half of melanomas: a BRAF inhibitor combined with a MEK inhibitor blocks the MAPK pathway at two points.
Mechanism of action
- BRAF V600E is a constantly active kinase that signals through MEK and ERK to drive proliferation.
- Vemurafenib, dabrafenib and encorafenib inhibit mutant BRAF; trametinib, cobimetinib and binimetinib inhibit MEK downstream.
- Combining them gives deeper responses and delays resistance; it also prevents the skin tumours that BRAF inhibitors alone provoke by paradoxically activating the pathway in normal cells.
Molecular targets
- Mutant BRAF kinase: Inhibitor
- MEK1/2: Inhibitor
Drugs in BRAF and MEK inhibitors
- Dabrafenib with trametinib
- Vemurafenib with cobimetinib
- Encorafenib with binimetinib
Therapeutic uses
- BRAF V600-mutant advanced melanoma, and after surgery for high-risk stage III
- BRAF-mutant lung cancer and colorectal cancer (encorafenib with an anti-EGFR antibody)
Diseases it treats
Adverse effects
- Fever (dabrafenib)
- Photosensitivity and rash (vemurafenib)
- Cutaneous squamous cell carcinomas, mainly with a BRAF inhibitor alone
- Reduced ejection fraction and retinal problems (MEK inhibitors)
Contraindications by condition
- Heart failure (MEK inhibitors) (Use with care): They can reduce the ejection fraction.
- Pregnancy (Contraindicated): They harm the fetus.
- Long QT (Use with care): Vemurafenib prolongs the QT interval.
Other cautions and interactions
- They are only for tumours with a BRAF V600 mutation; in BRAF wild-type tumours they can accelerate growth.
Connected topics
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 35, Anticancer Drugs, Kinase inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, BRAF & MEK inhibitors
Educational reference. Not medical advice, diagnosis or treatment.